{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:48:29Z","timestamp":1784735309478,"version":"3.55.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007496","name":"VA Biomedical Laboratory Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["OE 821\/1-1"],"award-info":[{"award-number":["OE 821\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37 AA020703"],"award-info":[{"award-number":["R37 AA020703"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AA026939"],"award-info":[{"award-number":["U01 AA026939"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AA24726"],"award-info":[{"award-number":["R01 AA24726"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018576","name":"Harrington Discovery Institute, University Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018576","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cmghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.jcmgh.2023.12.005","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T19:50:57Z","timestamp":1702756257000},"page":"423-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts"],"prefix":"10.1016","volume":"17","author":[{"given":"Burcin","family":"\u00d6zdirik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6281-825X","authenticated-orcid":false,"given":"Bernd","family":"Schnabl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmgh.2023.12.005_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41575-022-00690-y","article-title":"The microbiota and the gut-liver axis in primary sclerosing cholangitis","volume":"20","author":"Hov","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib2","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis: a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","article-title":"PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis","volume":"54","author":"Loftus","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/00365521.2017.1421705","article-title":"Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study","volume":"53","author":"Lindstr\u00f6m","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3350\/cmh.2012.18.4.337","article-title":"The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension","volume":"18","author":"Seo","year":"2012","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib8","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/hep.1840130425","article-title":"Biliary tract disease in rats with experimental small bowel bacterial overgrowth","volume":"13","author":"Lichtman","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib9","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1172\/JCI115996","article-title":"Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth","volume":"90","author":"Lichtman","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2018.05.018","article-title":"Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice","volume":"69","author":"Guicciardi","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41579-020-0438-4","article-title":"Gut microbial metabolites as multi-kingdom intermediates","volume":"19","author":"Krautkramer","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib14","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile acid signaling in metabolic disease and drug therapy","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","article-title":"TGR5 is essential for bile acid-dependent cholangiocyte proliferation in\u00a0vivo and in\u00a0vitro","volume":"65","author":"Reich","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2021.03.029","article-title":"Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis","volume":"75","author":"Reich","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib17","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","article-title":"The bile acid receptor FXR is a modulator of intestinal innate immunity","volume":"183","author":"Vavassori","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.24691","article-title":"A\u00a0biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes","volume":"55","author":"Hohenester","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib19","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib20","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jhep.2021.07.029","article-title":"Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver","volume":"75","author":"Gadaleta","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.autrev.2017.07.002","article-title":"Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases","volume":"16","author":"Li","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib23","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","article-title":"Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD","volume":"65","author":"Sabino","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/apt.15375","article-title":"Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis","volume":"50","author":"R\u00fchlemann","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib25","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.3748\/wjg.v23.i25.4548","article-title":"Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis","volume":"23","author":"Bajer","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib26","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1053\/j.gastro.2020.12.058","article-title":"Altered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis","volume":"160","author":"Kummen","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gutjnl-2021-326500","article-title":"Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC","volume":"72","author":"Awoniyi","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib28","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/gutjnl-2016-312533","article-title":"Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis","volume":"66","author":"Iwasawa","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/gutjnl-2018-317791","article-title":"Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis","volume":"69","author":"Lemoinne","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/gutjnl-2020-323565","article-title":"Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis","volume":"71","author":"Liu","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib31","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1136\/gutjnl-2019-320008","article-title":"Gut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species","volume":"69","author":"R\u00fchlemann","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gutjnl-2019-318416","article-title":"Alterations of the bile microbiome in primary sclerosing cholangitis","volume":"69","author":"Liwinski","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib35","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gutjnl-2018-317836","article-title":"Alterations of gut microbiome in autoimmune hepatitis","volume":"69","author":"Wei","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib37","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/apt.15754","article-title":"A\u00a0disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis","volume":"51","author":"Liwinski","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib38","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1186\/s12864-019-6251-7","article-title":"Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease","volume":"20","author":"Zhang","year":"2019","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/jgh.12694","article-title":"Association between specific mucosa-associated microbiota in Crohn's disease at the time of resection and subsequent disease recurrence: a pilot study","volume":"30","author":"De Cruz","year":"2015","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib40","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib94","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.3390\/ijms22136975","article-title":"The role of microbiota in primary sclerosing cholangitis and related biliary malignancies","volume":"22","author":"\u00d6zdirik","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib41","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41467-023-39029-9","article-title":"Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis","volume":"14","author":"Ichikawa","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib42","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1038\/s41564-019-0483-9","article-title":"Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC\/IBD diagnoses","volume":"4","author":"Vieira-Silva","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib43","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.cgh.2022.09.006","article-title":"Bile duct colonization with Enterococcus sp. associates with disease progression in primary sclerosing cholangitis","volume":"21","author":"Zigmond","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib44","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000156","article-title":"Biliary microbial patterns in primary sclerosing cholangitis are linked to poorer transplant-free survival","volume":"7","author":"\u00d6zdirik","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib53","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/hep.26447","article-title":"Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis","volume":"58","author":"Katt","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib45","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/ecco-jcc\/jjaa021","article-title":"A\u00a0pilot integrative analysis of colonic gene expression, gut microbiota, and immune infiltration in primary sclerosing cholangitis-inflammatory bowel disease: association of disease with bile acid pathways","volume":"14","author":"Quraishi","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/gutjnl-2016-311915","article-title":"The gut-adherent microbiota of PSC-IBD is distinct to that of IBD","volume":"66","author":"Quraishi","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib47","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fimmu.2019.00277","article-title":"Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases","volume":"10","author":"Parada Venegas","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib48","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/apt.13552","article-title":"The features of mucosa-associated microbiota in primary sclerosing cholangitis","volume":"43","author":"Torres","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib49","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.20041035","article-title":"Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis","volume":"200","author":"Eksteen","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib50","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nri1784","article-title":"Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease","volume":"6","author":"Adams","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib52","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MPG.0000000000002855","article-title":"Vedolizumab therapy in children with primary sclerosing cholangitis: data from the Pediatric Primary Sclerosing Cholangitis Consortium","volume":"71","author":"Laborda","year":"2020","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib54","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/hep.31140","article-title":"Monocytes as potential mediators of pathogen-induced T-helper 17 differentiation in patients with primary sclerosing cholangitis (PSC)","volume":"72","author":"Kunzmann","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jhep.2021.03.016","article-title":"Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4","volume":"75","author":"Poch","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib56","doi-asserted-by":"crossref","first-page":"eabi4354","DOI":"10.1126\/scitranslmed.abi4354","article-title":"Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis","volume":"14","author":"Shi","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib58","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1194\/jlr.R500013-JLR200","article-title":"Bile salt biotransformations by human intestinal bacteria","volume":"47","author":"Ridlon","year":"2006","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib57","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/gutjnl-2016-312354","article-title":"Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner","volume":"67","author":"Trivedi","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.27927","article-title":"Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis","volume":"63","author":"Tabibian","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib60","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/jhep.2001.24034","article-title":"Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver","volume":"33","author":"Beuers","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib61","doi-asserted-by":"crossref","first-page":"17810","DOI":"10.1074\/jbc.M209898200","article-title":"Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets","volume":"278","author":"Beuers","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib62","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/gut.2007.140871","article-title":"Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-\/PKA-dependent mechanism in rat liver","volume":"57","author":"Wimmer","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib63","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10715769709097792","article-title":"Secondary bile acid induced DNA damage in HT29 cells: are free radicals involved?","volume":"26","author":"Booth","year":"1997","journal-title":"Free Radic Res"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib64","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/hep.1840150409","article-title":"Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease","volume":"15","author":"Beuers","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib65","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s42255-021-00452-1","article-title":"Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling","volume":"3","author":"Schneider","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0009-8981(96)06305-X","article-title":"Hepatic levels of bile acids in end-stage chronic cholestatic liver disease","volume":"251","author":"Fischer","year":"1996","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib67","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.dld.2011.10.025","article-title":"Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study","volume":"44","author":"Trottier","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib68","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2012-302578","article-title":"Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases","volume":"62","author":"Duboc","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib69","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41564-018-0306-4","article-title":"Gut microbiome structure and metabolic activity in inflammatory bowel disease","volume":"4","author":"Franzosa","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib70","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1038\/s41467-023-38840-8","article-title":"Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis","volume":"14","author":"Gui","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cell.2004.07.002","article-title":"Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis","volume":"118","author":"Rakoff-Nahoum","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib72","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1126\/science.1219328","article-title":"Microbial exposure during early life has persistent effects on natural killer T cell function","volume":"336","author":"Olszak","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib73","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.1223490","article-title":"Interactions between the microbiota and the immune system","volume":"336","author":"Hooper","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib74","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/gut.2010.235408","article-title":"Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?","volume":"60","author":"Marelli","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib75","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cgh.2012.01.006","article-title":"Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis","volume":"10","author":"Navaneethan","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib76","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cgh.2011.08.027","article-title":"Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis","volume":"9","author":"Ngu","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib77","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.tim.2013.04.002","article-title":"The emerging world of the fungal microbiome","volume":"21","author":"Huffnagle","year":"2013","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib78","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/liv.15160","article-title":"Roles for the mycobiome in liver disease","volume":"42","author":"Zeng","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib79","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12281-010-0035-5","article-title":"Fungal biofilms: relevance in the setting of human disease","volume":"4","author":"Martinez","year":"2010","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib80","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-micro-091014-104330","article-title":"Candida albicans biofilms and human disease","volume":"69","author":"Nobile","year":"2015","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib81","first-page":"837","article-title":"Yeasts in the gut: from commensals to infectious agents","volume":"106","author":"Schulze","year":"2009","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib82","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/gutjnl-2016-313170","article-title":"Fungal dysbiosis in cirrhosis","volume":"67","author":"Bajaj","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib83","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/gutjnl-2015-310746","article-title":"Fungal microbiota dysbiosis in IBD","volume":"66","author":"Sokol","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib84","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2249.2003.02166.x","article-title":"Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases","volume":"132","author":"Muratori","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib85","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1128\/cdli.3.2.219-226.1996","article-title":"Specific antibody response to oligomannosidic epitopes in Crohn's disease","volume":"3","author":"Sendid","year":"1996","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib86","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.297.6656.1105","article-title":"Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease","volume":"297","author":"Main","year":"1988","journal-title":"BMJ"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib87","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1365-2036.2005.02417.x","article-title":"Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet","volume":"21","author":"Granito","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib88","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12020-010-9372-y","article-title":"Anti-Saccaromyces Cerevisiae antibodies (ASCA) are elevated in autoimmune thyroid disease ASCA in autoimmune thyroid disease","volume":"38","author":"Yaz\u0131c\u0131","year":"2010","journal-title":"Endocrine"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib89","first-page":"e4691","article-title":"Antibodies to brewer's yeast in rheumatoid arthritis","volume":"11","author":"Lichtenstein","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib90","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/cid\/cix948","article-title":"Management of an outbreak of Exophiala dermatitidis bloodstream infections at an outpatient oncology clinic","volume":"66","author":"Vasquez","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib91","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12879-018-3171-0","article-title":"Disseminated Exophiala dermatitidis causing septic arthritis and osteomyelitis","volume":"18","author":"Lang","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib92","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1099\/jmm.0.008706-0","article-title":"Systemic phaeohyphomycosis resembling primary sclerosing cholangitis caused by Exophiala dermatitidis","volume":"58","author":"Oztas","year":"2009","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib93","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1099\/jmm.0.002188-0","article-title":"Liver cirrhosis caused by Exophiala dermatitidis","volume":"58","author":"Hong","year":"2009","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib140","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ecco-jcc\/jju023","article-title":"The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II","volume":"9","author":"Rossen","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib144","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/ecco-jcc\/jjv204","article-title":"Characterization of intestinal microbiota in ulcerative colitis patients with and without primary sclerosing cholangitis","volume":"10","author":"Kevans","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib95","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2022.01.017","article-title":"Mucosal fungi promote gut barrier function and social behavior via Type 17 immunity","volume":"185","author":"Leonardi","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib96","article-title":"Intestinal fungi and antifungal secretory immunoglobulin A in Crohn's disease","volume":"14","author":"Sun","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib97","first-page":"331","article-title":"The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases","volume":"16","author":"Richard","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib98","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nri2939","article-title":"Immunity to fungal infections","volume":"11","author":"Romani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib99","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41401-022-00926-2","article-title":"Dectin-1 plays a deleterious role in high fat diet-induced NAFLD of mice through enhancing macrophage activation","volume":"44","author":"Wang","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib100","doi-asserted-by":"crossref","first-page":"18213","DOI":"10.18632\/oncotarget.15313","article-title":"AFB1 hepatocarcinogenesis is via lipid peroxidation that inhibits DNA repair, sensitizes mutation susceptibility and induces aldehyde-DNA adducts at p53 mutational hotspot codon 249","volume":"8","author":"Weng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib101","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1478-3231.2011.02474.x","article-title":"Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation","volume":"31","author":"Gursoy-Yuzugullu","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib102","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0006-291X(86)80575-7","article-title":"Expression of the c-Ha-ras and c-myc genes in aflatoxin B1-induced hepatocellular carcinomas","volume":"138","author":"Tashiro","year":"1986","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib103","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jhep.2019.09.029","article-title":"The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease","volume":"72","author":"Chu","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib104","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jhep.2009.01.023","article-title":"Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis","volume":"51","author":"Rudolph","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib105","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/s12879-014-0562-8","article-title":"Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis","volume":"14","author":"Rupp","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib106","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature10957","article-title":"Pathogen-induced human TH17 cells produce IFN-\u03b3 or IL-10 and are regulated by IL-1\u03b2","volume":"484","author":"Zielinski","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib107","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.chom.2023.02.001","article-title":"Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease","volume":"31","author":"Zeng","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib109","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A\u00a0triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib108","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis. A pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib111","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.20457","article-title":"Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial","volume":"40","author":"F\u00e4rkkil\u00e4","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib145","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/MJT.0000000000000102","article-title":"Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis","volume":"24","author":"Tabibian","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib112","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ajg.2008.14","article-title":"Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study","volume":"104","author":"Silveira","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib121","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib131","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.1840160315","article-title":"Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial","volume":"16","author":"Beuers","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib132","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib133","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib137","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib146","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A\u00a0randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib147","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib148","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s00535-010-0204-x","article-title":"Bezafibrate for the treatment of primary sclerosing cholangitis","volume":"45","author":"Mizuno","year":"2010","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib149","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/jhbp.281","article-title":"Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis","volume":"22","author":"Mizuno","year":"2015","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib141","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib110","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-0039-1688501","article-title":"Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis","volume":"39","author":"Shah","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib113","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hep.31560","article-title":"Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib114","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/gutjnl-2018-316599","article-title":"Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis","volume":"68","author":"Tan","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib115","doi-asserted-by":"crossref","first-page":"814","DOI":"10.14309\/ajg.0000000000000604","article-title":"Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: a conceptional framework","volume":"115","author":"Shah","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110211","article-title":"Long-term oral vancomycin for refractory inflammatory bowel diseases without Clostridium difficile infection: lessons from primary sclerosing cholangitis","volume":"144","author":"Du","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib117","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib118","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","volume":"149","author":"Moayyedi","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib119","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2018.20046","article-title":"Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial","volume":"321","author":"Costello","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib122","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib123","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/MEG.0b013e3282f5197e","article-title":"Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study","volume":"20","author":"Vleggaar","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib124","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1172\/JCI90562","article-title":"Intestinal fungi contribute to development of alcoholic liver disease","volume":"127","author":"Yang","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib125","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jhep.2021.11.029","article-title":"The fecal mycobiome in non-alcoholic fatty liver disease","volume":"76","author":"Demir","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib126","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL Clinical Practice Guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib127","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG Clinical Guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib128","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib129","doi-asserted-by":"crossref","first-page":"12260","DOI":"10.3748\/wjg.v20.i34.12260","article-title":"Prospective observational multicenter study to define a diagnostic algorithm for biliary candidiasis","volume":"20","author":"Lenz","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib130","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","article-title":"Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities","volume":"55","author":"Vesterhus","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib134","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.27074","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis","volume":"60","author":"Wunsch","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib135","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/hep4.1421","article-title":"A\u00a0prospective trial of withdrawal and reinstitution of ursodeoxycholic acid in pediatric primary sclerosing cholangitis","volume":"3","author":"Black","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib136","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2020.07.032","article-title":"Inter- and intra-individual variation, and limited prognostic utility, of serum alkaline phosphatase in a trial of patients with primary sclerosing cholangitis","volume":"19","author":"Trivedi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib138","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1365-2036.2011.04863.x","article-title":"High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis","volume":"34","author":"Imam","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib142","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A\u00a0mouse model of hepatocellular carcinoma: ectopic expression\u00a0of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcmgh.2023.12.005_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/hep-2017-0008","article-title":"Fibroblast growth factor 19, a double-edged sword","volume":"4","author":"Jansen","year":"2017","journal-title":"Hepat Oncol"}],"container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X23002187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X23002187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:28:48Z","timestamp":1778873328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352345X23002187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":147,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2352345X23002187"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmgh.2023.12.005","relation":{},"ISSN":["2352-345X"],"issn-type":[{"value":"2352-345X","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts","name":"articletitle","label":"Article Title"},{"value":"Cellular and Molecular Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2023.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}